Go t

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF 05 MAR -4 /

02/01/200

LOBBYING REGISTRATION

Lobbying Disclosure Act of 1995 (Section 4)

		1.	Effective Date of Registration _	02/01/20	
2. House Identifi	ication Number	Senate Identification Number			
REGISTRAN					
3. Registrant nan	ne Organization Health	Policy Source, Inc.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1+++11+1+1+1+1+1+1+1+1+1+1+1+1+1+1+1+1+1	
Address 1662	25 Dove Canyon Road		Suite 102-412	***************************************	
City San	Diego	State CA	Zip 92127	U	
4. Principal plac	e of business (if differen				
City Was	shington	State DC	Zip 20004	U.	
5. Telephone nui	mber and contact name		***************************************	***************************************	
202-3	888-6600 Con	_{tact} Ms. Monica Te	encate E-mail mtencate@he	althpolicysour	
6. General descr health care c	ription of registrant's bus consulting	ness r			
labele	bbying firm is required to file a se, ed "Self" and proceed to line 10. Novartis Corporation	Self	nt. Organizations employing in-house lobby	ists should check the	
Address 701	Pennsylvania Ave NW, S	Ste 725			
City Was	shington	State DC	Zip 20004	Country L	
8. Principal plac	ce of business (if differen				
City		State	Zip	Country	
9. General descripharmaceutic	ription of client's busines cal company	s or activities			
section has se	rved as a "covered executiv	e branch official" or "cov	Go to be by the client identified on line or l	hin two years of i	
Monica	Tencate				
Dan	Boston				
Jill	Canino				
•••••••	······································				
				,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

	······································
LD-1DS (Rev. 0403)	Page _1

Registrant Name Health Policy Source, Inc.				Client Name Novartis Corporation				
LOBBYING ISSUI 11. General lobbying issue MMM		nd the code to				Go to page 3 to add more		
12. Specific lobbying issue monitoring regulatory a and other pharmaceuti	and legisla	tive issues in		particular	y the Medicare p	prescription drug ben	efit, A	
AFFILIATED ORe 13. Is there an entity other a semiannual period ar No ⇔ Go to line	than the cl id in whole	ient that contrib		ervises or c	ontrols the registr	ant's lobbying activitie	ant in s?	
Name		Address		,	Principal place of Busine (city and state or count			
FOREIGN ENTIT 14. Is there any foreign en	ntity that:					Go to page 3 to add mod	re fore	
b) directly or in the client or	ndirectly, in any organice of the cli	n whole or in m zation identific	ajor part, pl	ans, superv ; O r	vises, controls, dire	ied on line 13: Or ects, finances or subsid		
x No ⇔ Sign and d	-	istration.		Yes⇔	•	st of this section for eac teria above, then sign a		
Name	Street Addre City		vince Country		cipal place of business d state or country)	Amount of contribution for lobbying activities		
						For	m Co	

Printed Name and Title Monica Tencate, President

k